Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mingfang Zhao

Showing results (71-80 of 82) with videos related to

Pageof 9
Sort By:
The Lancet Regional Health. Western Pacific|January 6, 2025
Consensus on the lung cancer management after third-generation EGFR-TKI resistanceQing Zhou, Hongyun Zhao, Shun Lu, et al.
Signal Transduction and Targeted Therapy|July 27, 2025
Efficacy and safety of IBI351 (fulzerasib) monotherapy in KRAS<sup>G12C</sup> inhibitor-naïve Chinese patients with KRAS<sup>G12C</sup>-mutated metastatic colorectal cancer: a pooled analysis from phase I part of two studiesYing Yuan, Yanhong Deng, Yongdong Jin, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 10, 2024
Efficacy and Safety of KRASG12C Inhibitor IBI351 Monotherapy in Patients With Advanced NSCLC: Results From a Phase 2 Pivotal StudyQing Zhou, Xiangjiao Meng, Longhua Sun, et al.
Cancer Letters|July 25, 2025
Advanced Ensemble Staking Model Employing cfDNA Fragmentation for Early Detection of Esophageal and Gastric CancerShitong Cheng, Yusong Luo, Xiaolong Dong, et al.
European Journal of Cancer (Oxford, England : 1990)|October 2, 2024
Potent covalent irreversible inhibitor of KRAS G12C IBI351 in patients with advanced solid tumors: First-in-human phase I studyQing Zhou, Nong Yang, Mingfang Zhao, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 31, 2017
Efficacy of Thalidomide in Preventing Delayed Nausea and Vomiting Induced by Highly Emetogenic Chemotherapy: A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase III Trial (CLOG1302 study)Lingyun Zhang, Xiujuan Qu, Yuee Teng, et al.
Journal of the National Cancer Center|July 22, 2024
Chinese expert consensus on the diagnosis and treatment of bone metastasis in lung cancer (2022 edition)Jianchun Duan, Wenfeng Fang, Hairong Xu, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 30, 2023
Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of YK-029A in Treatment-Naive Patients With Advanced NSCLC Harboring EGFR Exon 20 Insertion Mutations: A Phase 1 TrialJianchun Duan, Lin Wu, Kunyu Yang, et al.
Med (New York, N.Y.)|April 12, 2025
Multidisciplinary expert consensus on diagnosis and treatment of multiple lung cancersKezhong Chen, Anwen Liu, Changli Wang, et al.
European Journal of Cancer (Oxford, England : 1990)|December 2, 2025
Garsorasib in patients with KRAS G12C-mutated non-small-cell lung cancer: A pooled analysis of phase 1/2 studyZhengbo Song, Ziming Li, Yiping Zhang, et al.
Pageof 9

Showing results (71-80 of 82) with videos related to

Sort By:
Pageof 9
The Lancet Regional Health. Western Pacific|January 6, 2025
Consensus on the lung cancer management after third-generation EGFR-TKI resistanceQing Zhou, Hongyun Zhao, Shun Lu, et al.
Signal Transduction and Targeted Therapy|July 27, 2025
Efficacy and safety of IBI351 (fulzerasib) monotherapy in KRAS<sup>G12C</sup> inhibitor-naïve Chinese patients with KRAS<sup>G12C</sup>-mutated metastatic colorectal cancer: a pooled analysis from phase I part of two studiesYing Yuan, Yanhong Deng, Yongdong Jin, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 10, 2024
Efficacy and Safety of KRASG12C Inhibitor IBI351 Monotherapy in Patients With Advanced NSCLC: Results From a Phase 2 Pivotal StudyQing Zhou, Xiangjiao Meng, Longhua Sun, et al.
Cancer Letters|July 25, 2025
Advanced Ensemble Staking Model Employing cfDNA Fragmentation for Early Detection of Esophageal and Gastric CancerShitong Cheng, Yusong Luo, Xiaolong Dong, et al.
European Journal of Cancer (Oxford, England : 1990)|October 2, 2024
Potent covalent irreversible inhibitor of KRAS G12C IBI351 in patients with advanced solid tumors: First-in-human phase I studyQing Zhou, Nong Yang, Mingfang Zhao, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 31, 2017
Efficacy of Thalidomide in Preventing Delayed Nausea and Vomiting Induced by Highly Emetogenic Chemotherapy: A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase III Trial (CLOG1302 study)Lingyun Zhang, Xiujuan Qu, Yuee Teng, et al.
Journal of the National Cancer Center|July 22, 2024
Chinese expert consensus on the diagnosis and treatment of bone metastasis in lung cancer (2022 edition)Jianchun Duan, Wenfeng Fang, Hairong Xu, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 30, 2023
Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of YK-029A in Treatment-Naive Patients With Advanced NSCLC Harboring EGFR Exon 20 Insertion Mutations: A Phase 1 TrialJianchun Duan, Lin Wu, Kunyu Yang, et al.
Med (New York, N.Y.)|April 12, 2025
Multidisciplinary expert consensus on diagnosis and treatment of multiple lung cancersKezhong Chen, Anwen Liu, Changli Wang, et al.
European Journal of Cancer (Oxford, England : 1990)|December 2, 2025
Garsorasib in patients with KRAS G12C-mutated non-small-cell lung cancer: A pooled analysis of phase 1/2 studyZhengbo Song, Ziming Li, Yiping Zhang, et al.
Pageof 9